Ezetimibe With Atorvastatin
Treatment in conjunction with dietary therapy and exercise for co-administration of ezetimibe with atorvastatin in patients whose cholesterol levels are inadequately controlled with a statin alone, or patients with homozygous familial hypercholesterolaemia.
Access path
- Jul 2012Recommended
vs ezetimibe and atorvastatin given concomitantly (as separate…
- PBS listing · Not applicable
Cost-effectiveness
Cost-minimisation analysis presented; no ICER calculated
The PBAC noted that it could only recommend a higher price for the ezetimibe and atorvastatin co-pack if it is satisfied that the co-pack provides, for some patients, a significant improvement in efficacy or reduction of toxicity over the alternative therapy or therapies. PBAC · 2012
Decision context
PopulationPatients with hypercholesterolaemia whose cholesterol levels are inadequately controlled with a statin at maximum tolerated dose, including those with coronary heart disease, diabetes mellitus, peripheral vascular disease, heterozygous familial hypercholesterolaemia, symptomatic cerebrovascular disease, family history of coronary heart disease, or hypertension; also patients with homozygous familial hypercholesterolaemia
Why it was knocked back
- concerns over labelling and packaging of the co-pack and risk of incorrect patient use, failure to demonstrate superiority in comparative efficacy and safety over ezetimibe/simvastatin fixed dose combination, proposed price higher than alternative therapy without demonstrated clinical benefit, inadequate indirect comparison evidence
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2012 | Recommended | ezetimibe and atorvastatin given concomitantly (as separate tablets); ezetimibe/simvastatin fixed dose combination as se | — | RCT · LDL-C |